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Abstract
Objective of study To evaluate the efficacyof radiofrequency
ablation (RFA) of ventricular tachycardia (VT) using non-
contact electro-anatomic mapping in patients with arrhythmo-
genic right ventricular dysplasia/cardiomyopathy (ARVD/C).
Methods Fifteen consecutive patients (44±15 years) with
ARVD/C and symptomatic VTs were studied. Eight patients
had syncopal VTs. Two patients had recurrent VT while on
AICD; in three patients, RFA was done prior to AICD
implantation, and ten patients refused AICD. After obtaining
activation maps, first, the clinical VTwas targeted, and then,
other VTs were sought.
Results Twenty-five inducible VTs were mapped, and 22 of
themweresuccessfullyablated.In13outof15patients,allthe
clinical and inducible VTs were ablated. In two patients, non-
clinical inducible VTs could not be ablated. At 25±16 months
(2–52 months), all patients remained asymptomatic. Antiar-
rhythmic medications were discontinued after 6 months. Two
patients had recurrence of non-clinical VT on follow-up.
There were no episodes of asymptomatic VT recorded in five
patients with AICD.
Conclusion A majority of induced VT in patients with
ARVD/C can be successfully mapped and ablated using the
non-contact Ensite Array Mapping system with good long-
term VT-free outcome. Ablation can be a useful adjunct to
AICD implantation in such patients.
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Abbreviations
ARVD/C Arrhythmogenic right ventricular dysplasia/
cardiomyopathy
PVCs Premature ventricular contractions
AICD Automated implantable cardioverter–
defibrillator
RFA Radiofrequency catheter ablation
3D Three-dimensional
VT Ventricular tachycardia
ECG Electrocardiogram
RV Right ventricular
RVOT Right ventricular outflow tract
Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is an inherited cardiomyopathy characterized by
fibro-fatty replacement primarily of right ventricular mus-
cle. This results in a heterogeneous structure of the right
ventricular myocardium which causes ventricular arrhyth-
mias, including PVCs, and non-sustained or sustained
ventricular tachycardia and sudden death due to ventric-
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right and left ventricles may lead to congestive heart
failure [1–3]. ARVD/C is uncommon, but may account
f o ru pt o2 0 %o fc a s e so fs u d d e nd e a t ha m o n gy o u n g
individuals [4–7].
Since patients with ARVD/C are at significantly high risk
of sudden cardiac death, most people with this condition are
advised automated implantable cardioverter–defibrillator
(AICD) implantation. However, high rates of appropriate
AICD firing among patients with ARVD/C have been
reported in multiple studies [8–12]. Consequently, adjunc-
tive treatment with antiarrhythmic drug therapy and/or
radiofrequency catheter ablation (RFA) is commonly
recommended.
The acute- and long-term efficacy of radiofrequency
catheter ablation in patients with ARVD/C still remains
unclear. Most previous studies have used either conven-
tional mapping alone or a combination of conventional and
3D electroanatomical mapping, thus clouding the results
[12–17].
We report the acute- and intermediate-term results of
RFA using the non-contact Ensite Array Mapping system
(St. Jude Medical, St. Paul, MN) in Indian patients with
ARVD/C. All patients met the criteria for ARVD/C
diagnosis as defined by the International Task Force [18].
1 Methods
All patients who underwent RFA guided by non-contact
electroanatomical mapping and satisfied the International
Task Force criteria for ARVD/C were included in a
prospective analysis. Each patient had previously experi-
enced two or more episodes of sustained VT. All patients
gave written informed consent for RFA.
Clinical VT(s) were defined by several techniques,
including a comparison of 12-lead electrocardiographic
morphologies of induced and spontaneous VT, and when
a 12-lead electrocardiogram of the clinical VT was not
available, by comparison of induced and spontaneous VT
cycle lengths. Electroanatomical mapping was used to
facilitate ablation during all procedures in 15 patients
[19, 20].
The EnSite Array Mapping system is a computerized
system that creates three-dimensional electroanatomical
maps without the need for point-by-point contact electro-
grams and was used in all the patients. In this system, non-
contact balloon catheter creates virtual unipolar electro-
grams using a mathematical inverse solution to estimate the
electrical potentials which allows for non-contact mapping
of conduction through a cardiac chamber in a single cycle
of the tachycardia. This system is particularly useful for
mappingandablationofVTincardiomyopathiesasactivation
maps for non-sustained as well as hemodynamically unstable
VTscanbeobtainedeasily.Theendocardial breakthroughsite
of the VT was defined at the point of onset of a sharp QS
deflection on the unipolar virtual electrogram. The endo-
cardial breakthrough sites were further confirmed using
entrainment and/or pace mapping. Then, linear or circum-
ferential RF lesions were given to encompass a wide area
around this site (Fig. 1). Low-amplitude, diastolic potentials
were also invariably seen at the successful ablation sites.
Fig. 1 Ensite Map of VT in a patient with VT of multiple
morphologies. All the VTs were, however, shown to turn around a
single area in the RV (red line-white arrow). Ablation along this line
rendered all the VTs non-inducible; 52 months follow-up has shown
one episode of asymptomatic slow VT. VT ventricular tachycardia; RV
right ventricular
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electrograms and diastolic potentials could also be recorded
at sites in the RV not responsible for VT.
The Ensite Array catheter was positioned either at the
RV apex and/or the RVOT depending on the expected site
of origin of VT from the scalar ECG morphology. VT was
induced using programmed stimulation. Induction protocol
consisted of programmed stimulation at two cycle lengths
at two RV sites and up to three extrastimuli. Drugs such as
isoprenaline were not used in any patient for induction. The
first goal was to target the clinical VT and then look for any
other VT.
Standard radiofrequency energy (60 W power, 60°C
temperatures for 60 s) delivered through 4-mm tipped
deflectable ablation catheters were used for each of the
ablation procedure. Ablation of a particular morphology of
VT was considered successful if the VT terminated during
radiofrequency application and/or it could not be induced
on repeated stimulation. Procedural success was defined as
total when all of the inducible VTs could be successfully
mapped and ablated, partial when not all of the inducible
VTs were successfully ablated, but the clinical VT was
successfully ablated, and failure if none of the inducible
VTs could be ablated successfully.
1.1 Follow-up
Patients were followed up routinely in out-patient clinics;
the patient underwent monthly 24-h Holter monitoring for
6 months and then three monthly Holter monitoring.
Patients were also advised to strictly report any symptom
of palpitation or syncope/presyncope. They were also told
to have a12-lead electrogram taken in case they developed
palpitation. AICD interrogation reports from patients with
AICD were analyzed whenever available. Appropriateness
of AICD intervention was defined using the standard
criteria. VT recurrence was defined as an appropriate AICD
intervention or the occurrence of sustained VT of at least
30-s duration or any hemodynamically significant VT
subsequent to the ablation procedure as documented by a
12-lead electrocardiogram, an event monitor, or a 24-hHolter
monitor. The time to VT recurrence after each ablation
procedure was noted. Long-term success was defined as the
absence of recurrence of VT over follow-up.
2 Results
Study population A total of 15 ARVD/C patients with at
least two episodes of clinical VT underwent catheter
ablation for VT. The mean age at the time of the procedure
was 44±15 years. Twelve (80%) of the 15 patients were
male. All patients were symptomatic, and eight patients had
syncopal VT. All patients were advised AICD implantation
in view of the progressive nature of their disease and the
standard recommendations in such patients. Two patients
were taken up for ablation of recurrent VT occurring while
on an AICD; three underwent AICD implantation following
the RF ablation, and the other ten patients declined AICD
due to financial constrains. In one patient, the ablation was
done for recurrence following a previous ablation procedure
done using conventional mapping technique.
Electrophysiology study, mapping, and ablation Table 1
shows the electrophysiological details of each of the 15
patients. Four patients had clinical VT with multiple mor-
phologies. All patients had VT induced during baseline
electrophysiological testing with multiple VT morphology
induced in six patients. In four patients, the induced non-
sustained VT with a fall in blood pressure but the short
duration was enough to get relevant information on the non-
contact map for guiding ablation. In one patient, VT induced
afterablationoftheclinicalVTcausedhemodynamiccollapse
requiring DC cardioversion; however, the short run of VT
prior to cardioversion was sufficient to map the tachycardia
(Fig. 2). Mapping of VT was performed using 3-dimensional
electroanatomical mapping with the Ensite Array catheter
positioned in RVapex in eight patients and RVoutflow tract
in seven patients. Thirteen patients had all their VTs coming
from a single region (RV apex or the outflow tract), while
one had VTs originating from the apical as well as the
outflow tract region (Fig. 2). In one patient, the 3D mapping
showed breakthrough in the outflow tract. Intracardiac
electrograms, however, showed a sharp potential, which
followed the RV electrogram during sinus rhythm, but
preceded it during VT (Fig. 3). This potential was mapped
to originate in the pulmonary artery. While ablation at the
RVoutflow tract failed to eliminate the arrhythmia, ablation
within the pulmonary artery successfully terminated the
arrhythmia and rendered it non-inducible. In all 26 VTs, all
clinical VTs were mapped, and 23 VTs were ablated with an
acute procedural success rate of 88%.
All the inducible VTs were ablated successfully in 13
patients; in two patients, non-clinical inducible VTs could not
beablated.The clinical VTwas successfully ablatedandcould
notbere-inducedwithprogrammedelectricalstimulationinall
the patients with an acute clinical success rate of 100%. There
was no peri-procedural complication, and all patients were
discharged from the hospital following 48 h of the procedure.
Long-term follow-up The follow-up duration between the
first ablation procedure and the lastout-patient clinicvisit was
25±16 months (range, 2 to 52 months). All patients remained
asymptomatic. Routine monthly Holter recordings of all
patients for 6 months were analyzed, and there were no
episodes of sustained VT, and the numbers of ventricular
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werediscontinuediftherewasnorecurrenceofVTforatleast
6m o n t h s( T a b l e2). Antiarrhythmic medication could be
withdrawn in all patients after 6–8 months of ablation. One
patient had a recurrence of slow VT at the rate of 146 bpm,
after 17 weeks of ablation which was clinically silent and
was picked up on Holter. One patient who underwent AICD
implantation after ablation had an appropriate therapy for a
Fig. 2 Electrocardiograms and endocardial activation maps in a patient
having VTs with two different morphologies and cycle lengths. One VT
was ablated successfully in the RVOT region, whereas the other one was
seen to originate more apically in the RV. VT ventricular tachycardia; RV
right ventricular
Table 1 Electrophysiological details of each of the 15 patients
Subject
number
Age,
years
Syncopal
VT
Number of
clinical VTs
ICD before
RFA
Number of
VT induced
Number of
VT ablated
ICD after
ablation
VT recurrence Follow-up,
months
1 52 Yes 3 No 4 3 No 1-Slow VT 53
2 8 Yes 1 No 1 1 No No recurrence 45
3 48 Yes 1 Yes 1 1 NA No recurrence 44
4 44 Yes 2 No 2 2 No No recurrence 38
5 58 Yes 1 No 1 1 Yes 1 37
6 32 No 1 No 1 1 No No recurrence 33
7 56 No 3 No 3 3 Yes No recurrence 34
8 49 Yes 1 No 3 1 Yes No recurrence 28
9 60 Yes 1 No 1 1 No No recurrence 24
10 48 No 1 Yes 1 1 NA No recurrence 16
11 33 Yes 3 No 3 3 No No recurrence 13
12 36 No 1 No 2 2 No No recurrence 11
13 20 No 1 No 1 1 No No recurrence 7
14 34 No 1 No 1 1 No No recurrence 6
15 39 No 1 No 1 1 No No recurrence 3
VT ventricular tachycardia, ICD implantable cardioverter defibrillator, NA not applicable
144 J Interv Card Electrophysiol (2011) 31:141–147single episode of recurrence of VT, 21 months after the
procedure. In the five patients with ICDs, there were no
asymptomatic episodes detected nor were there any detected
on Holter monitors in the patients without ICDs.
3 Discussion
Our results show that catheter ablation of VT in patients
with ARVD/C is associated with high acute procedural
success and good intermediate-term outcomes with the use
of non-contact electroanatomical mapping systems to guide
the ablation.
In 1998, Ellison et al. [15] reported the acute- and long-
term outcome of catheter ablation in five ARVD/C patients.
Duringameanfollow-upof17months,noneofthesepatients
had recurrent VT; however, three patients were continuing on
antiarrhythmic drugs. In 2003, Reithmann et al. [21] used
electroanatomical mapping system to ablate VT in five
patients with ARVD/C. During a mean follow-up of
Fig. 3 Ventricular tachycardia originating in the pulmonary artery. Note sharp potential (arrow) following RV potential during sinus rhythm (a)a n d
preceding the RV potential during VT (b)
Table 2 Antiarrhythmic medications
Subject
number
Age,
years
Pre-ablation
VPC frequency
VPC/24 h
Post-ablation
VPC frequency
VPC/24 h
Antiarrhythmic
drugs used prior
to ablation
Antiarrhythmic
drugs used
after ablation
Duration of
antiarrhythmic
drugs after ablation
(months)
Follow-up
(months)
1 52 14,524 4,658 Amiodarone and metoprolol Amiodarone 7 53
2 8 12,457 9,854 Amiodarone Amiodarone 7 45
3 48 9,586 3,567 Amiodarone and metoprolol Amiodarone 8 44
4 44 25,463 11,287 Amiodarone Amiodarone 6 38
5 58 4,502 2,146 Amiodarone and metoprolol Amiodarone 7 37
6 32 3,589 118 Amiodarone and metoprolol Amiodarone 7 33
7 56 12,456 5,478 Amiodarone and metoprolol Amiodarone 7 34
8 49 9,845 2,458 Amiodarone Amiodarone 6 28
9 60 2,589 452 Amiodarone Amiodarone 6 24
10 48 11,244 245 Amiodarone and metoprolol Amiodarone 6 16
11 33 8,574 1,142 Amiodarone Amiodarone 6 13
12 36 1,554 1,283 Amiodarone Amiodarone 7 11
13 20 15,789 8,457 Amiodarone and metoprolol Amiodarone 6 7
14 34 1,145 1,352 Amiodarone and metoprolol Amiodarone 6 6
15 39 8,569 3,478 Amiodarone Amiodarone 3 3
VPC ventricular premature complexes
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amiodarone continued in three patients.
Use of electroanatomical mapping has also been reported
by Marchlinski et al. [22] and Verma et al. [23]. In
Marchlinski’s study acute success, defined as the absence
of all inducible VTs, was achieved in 14 (74%) of 19
patients. During a mean follow-up of 27±22 months, 17
(89%) of 19 patients were free of recurrent VT. However, in
this series, repeat ablation procedures were required in 68%
of patients, and the use of antiarrhythmic drugs were not
reported. Thus, the success rates of a single procedure were
low. In Verma’s study, catheter ablation in 22 patients with
ARVD/C, each of whom had hemodynamically unstable
VT, was reported. Acute success with no inducible VT at
the end of the procedure was achieved in 18 (82%) patients,
with VT recurrence rates despite continued antiarrhythmic
therapy of 23%, 27%, and 47% at 1, 2, and 3 years,
respectively.
Catheter ablation results The results of this study are in
keeping with the high success rate reported by Ellison et al.
[15] and Marchlinski et al. [22]. However, it differs from
studies by Dalal et al. [17], Reithmann et al. [21], and
Verma et al. [23] due to the considerable recurrence rate
reported in these reports. Reithmann et al. [21] reported a
40% recurrence rate during a mean follow-up of 7 months,
and Verma et al. [23] reported a recurrence rate of 47% at
3 years of follow-up.
The dichotomy in the procedural success rates have been
tried to be explained on the basis of the different modes of
mappingusedinthepreviousstudies. Substratebaseablation
using 3D electroanatomical mapping has been used with
good success rates in ablation of VT in complex substrates
such aspost-infarction [24] and cardiomyopathies; however,
in the study by Dalal et al. [17], only 21% patients had
ablation done using 3D electroanatomical mapping. Fur-
thermore, all the studies alluded to above have used point-
by-point-based mapping and ablation systems. Moreover,
most of the earlier large studies have pooled data from
several centers, with recruitment rates as low as two
patients from a single center, resulting in confounding,
non-uniform results [17, 22, 23]. Our study used the non-
contact mapping system which has a potential advantage in
this setting, as it allows mapping of non-sustained as well
as hemodynamically unstable VTs. This is agreement with
the study by Yao et al. [25] who used non-contact mapping
in similar subset of patients.
Epicardial mapping and ablation has also been used
successfully in patients with ventricular tachycardias [26–28].
Recently, Garcia et al. [29] have published their experience
with epicardial mapping and combined endocardial and
epicardial ablation in patients with ARVD/C who had an
earlier failed endocardial procedure with 10/13 patients (77%)
remaining free from VT at 18 months follow-up. This has
added a new approach in our armamentarium to ablate
ventricular tachycardia in ARVD/C. The relative absence of
epicardial VTs in our study was a little surprising and could
not be easily explained. This, however, does not dilute the
feasibility and importance of catheter ablation of ventricular
tachycardia in ARVD/C.
Limitations of the study Our study was limited by the fact
that only five patients had AICD implanted and, hence, true
recurrence of asymptomatic VT could be assessed only in
these patients; however, the other patients had regular
clinical and Holter-based follow-up and their recurrence
rates assessed.
Another limitation is the relatively short duration of
follow-up in many patients, and four patients have not yet
completed 6 months of drug-free follow-up.
Our study suggests that using non-contact mapping, which
has an advantage of mapping even non-sustained or hemody-
namically unstable VT, to guide the ablation strategy
improves the acute- and intermediate-term success rates of
ablation in these patients as compared with earlier reported
case series that have not used this mapping technology.
In conclusion, ablation guided by non-contact mapping
may prove to be an attractive complement to AICD in
preventing VT and sudden cardiac death in patients with
ARVD/C.
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